It has been proposed that binge eating reflects a pathological compulsion driven by the “addictive” properties of foods. Proponents of this argument highlight the large degree of phenomenological and diagnostic overlap between binge eating disorder (BED) and substance use disorders (SUDs), including loss of control over how much is consumed and repeated unsuccessful attempts to abstain from consumption, as well as commonalities in brain structures involved in food and drug craving. To date, very little attention has been given to an additional behavioral symptom that BED shares with SUDs—sleep dysregulation—and the extent to which this may contribute to the pathophysiology of BED. Here, we review studies examining sleep outcomes in patients with BED, which collectively point to a heightened incidence of sleep abnormalities in BED. We identify the orexin (hypocretin) system as a potential neurobiological link between compulsive eating and sleep dysregulation in BED, and provide a comprehensive update on the evidence linking this system to these processes. Finally, drawing on evidence from the SUD literature indicating that the orexin system exhibits significant plasticity in response to drugs of abuse, we hypothesize that chronic palatable food consumption likewise increases orexin system activity, resulting in dysregulated sleep/wake patterns. Poor sleep, in turn, is predicted to exacerbate binge eating, contributing to a cycle of uncontrolled food consumption. By extension, we suggest that pharmacotherapies normalizing orexin signaling, which are currently being trialed for the treatment of SUDs, might also have utility in the clinical management of BED.
Subscribe to Journal
Get full journal access for 1 year
only $30.69 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
American Psychiatric A, American Psychiatric A, Force DSMT. Diagnostic and statistical manual of mental disorders: DSM-5. 2013.
McCuen-Wurst C, Ruggieri M, Allison KC. Disordered eating and obesity: associations between binge-eating disorder, night-eating syndrome, and weight-related comorbidities. Ann N Y Acad Sci. 2018;1411:96–105.
Ghaderi A, Odeberg J, Gustafsson S, Råstam M, Brolund A, Pettersson A. et al. Psychological, pharmacological, and combined treatments for binge eating disorder: a systematic review and meta-analysis. PeerJ. 2018;6:e5113
Wilson GT, Wilfley DE, Agras WS, Bryson SW. Psychological treatments of binge eating disorder. Arch Gen Psychiatry. 2010;67:94–101.
Linardon J. Rates of abstinence following psychological or behavioral treatments for binge-eating disorder: meta-analysis. Int J Eat Disord. 2018;51:785–97.
Appolinario JC, Nardi AE, McElroy SL. Investigational drugs for the treatment of binge eating disorder (BED): an update. Expert Opin Invest Drugs. 2019;28:1081–1094.
McElroy SL, Hudson JI, Mitchell JE, Wilfley D, Ferreira-Cornwell MC, Gao J, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72:235–46.
McElroy SL, Hudson J, Ferreira-Cornwell MC, Radewonuk J, Whitaker T, Gasior M. Lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder: results of two pivotal phase 3 randomized controlled trials. Neuropsychopharmacology. 2016;41:1251–60.
Hudson JI, McElroy SL, Ferreira-Cornwell MC, Radewonuk J, Gasior M. Efficacy of lisdexamfetamine in adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2017;74:903–10.
Pursey KM, Stanwell P, Gearhardt AN, Collins CE, Burrows TL. The prevalence of food addiction as assessed by the Yale Food Addiction Scale: a systematic review. Nutrients. 2014;6:4552–90.
Innamorati M, Imperatori C, Balsamo M, Tamburello S, Belvederi Murri M, Contardi A, et al. Food Cravings Questionnaire-Trait (FCQ-T) discriminates between obese and overweight patients with and without binge eating tendencies: the Italian version of the FCQ-T. J Pers Assess. 2014;96:632–9.
Schulte EM, Grilo CM, Gearhardt AN. Shared and unique mechanisms underlying binge eating disorder and addictive disorders. Clin Psychol Rev. 2016;44:125–39.
Fletcher PC, Kenny PJ. Food addiction: a valid concept? Neuropsychopharmacology. 2018;43:2506–13.
Meule A, Küppers C, Harms L, Friederich HC, Schmidt U, Blechert J, et al. Food cue-induced craving in individuals with bulimia nervosa and binge-eating disorder. PloS ONE. 2018;13:e0204151.
Wonderlich JA, Breithaupt LE, Crosby RD, Thompson JC, Engel SG, Fischer S. The relation between craving and binge eating: integrating neuroimaging and ecological momentary assessment. Appetite. 2017;117:294–302.
Carlier N, Marshe VS, Cmorejova J, Davis C, Müller DJ. Genetic similarities between compulsive overeating and addiction phenotypes: a case for “food addiction”? Curr Psychiatry Rep. 2015;17:96.
Brown RM, Kupchik YM, Spencer S, Garcia-Keller C, Spanswick DC, Lawrence AJ, et al. Addiction-like synaptic impairments in diet-induced obesity. Biol Psychiatry. 2017;81:797–806.
Johnson PM, Kenny PJ. Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats. Nat Neurosci. 2010;13:635–41.
Wiers CE, Zhao J, Manza P, Murani K, Ramirez V, Zehra A, et al. Conscious and unconscious brain responses to food and cocaine cues. Brain Imaging Behav. 2021;15:311–9.
Volkow ND, Wise RA, Baler R. The dopamine motive system: implications for drug and food addiction. Nat Rev Neurosci. 2017;18:741–52.
Volkow ND, Wang GJ, Fowler JS, Tomasi D, Baler R. Food and drug reward: overlapping circuits in human obesity and addiction. Curr Top Behav Neurosci. 2012;11:1–24.
Grilo CM, White MA, Masheb RM. DSM-IV psychiatric disorder comorbidity and its correlates in binge eating disorder. Int J Eat Disord. 2009;42:228–34.
Schreiber LR, Odlaug BL, Grant JE. The overlap between binge eating disorder and substance use disorders: diagnosis and neurobiology. J Behav Addict. 2013;2:191–8.
Gearhardt AN, Corbin WR, Brownell KD. Preliminary validation of the Yale Food Addiction Scale. Appetite 2009;52:430–6.
Gearhardt AN, White MA, Masheb RM, Morgan PT, Crosby RD, Grilo CM. An examination of the food addiction construct in obese patients with binge eating disorder. Int J Eat Disord. 2012;45:657–63.
Hebebrand J, Gearhardt AN. The concept of “food addiction” helps inform the understanding of overeating and obesity: NO. Am J Clin Nutr. 2021;113:268–73.
Finlayson G. Food addiction and obesity: unnecessary medicalization of hedonic overeating. Nat Rev Endocrinol. 2017;13:493–8.
Gearhardt AN, Hebebrand J. The concept of “food addiction” helps inform the understanding of overeating and obesity: YES. Am J Clin Nutr. 2021;113:263–67.
Chakravorty S, Vandrey RG, He S, Stein MD. Sleep management among patients with substance use disorders. Med Clin North Am. 2018;102:733–43.
Roehrs TA, Roth T. Sleep disturbance in substance use disorders. Psychiatr Clin North Am. 2015;38:793–803.
Logan RW, Hasler BP, Forbes EE, Franzen PL, Torregrossa MM, Huang YH, et al. Impact of sleep and circadian rhythms on addiction vulnerability in adolescents. Biol Psychiatry. 2018;83:987–96.
Falcón E, McClung CA. A role for the circadian genes in drug addiction. Neuropharmacology. 2009;56:91–96.
Lydon-Staley DM, Cleveland HH, Huhn AS, Cleveland MJ, Harris J, Stankoski D, et al. Daily sleep quality affects drug craving, partially through indirect associations with positive affect, in patients in treatment for nonmedical use of prescription drugs. Addictive Behav. 2017;65:275–82.
Angarita GA, Canavan SV, Forselius E, Bessette A, Pittman B, Morgan PT. Abstinence-related changes in sleep during treatment for cocaine dependence. Drug Alcohol Depend. 2014;134:343–7.
James MH, Aston-Jones G. Introduction to the Special Issue: “making orexin-based therapies for addiction a reality: what are the steps from here?”. Brain Res. 2020;1731:146665.
American Academy of Sleep M. International Classification of Sleep Disorders—Third Edition (ICSD-3). Diagnostic and coding manual. 2014.
Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. Chest. 2014;146:1387–94.
Watson R, Bakos L, Compton P, Gawin F. Cocaine use and withdrawal: the effect on sleep and mood. Am J Drug Alcohol Abuse. 1992;18:21–28.
Johanson CE, Roehrs T, Schuh K, Warbasse L. The effects of cocaine on mood and sleep in cocaine-dependent males. Exp Clin Psychopharmacol. 1999;7:338–46.
Young-McCaughan S, Miaskowski C. Measurement of opioid-induced sedation. Pain Manag Nurs. 2001;2:132–49.
Young-McCaughan S, Miaskowski C. Definition of and mechanism for opioid-induced sedation. Pain Manag Nurs. 2001;2:84–97.
Lewis SA, Oswald I, Evans JI, Akindele MO, Tompsett SL. Heroin and human sleep. Electroencephalogr Clin Neurophysiol. 1970;28:374–81.
Kenny TE, Van Wijk M, Singleton C, Carter JC. An examination of the relationship between binge eating disorder and insomnia symptoms. Eur Eat Disord Rev. 2018;26:186–96.
Vardar E, Caliyurt O, Arikan E, Tuglu C. Sleep quality and psychopathological features in obese binge eaters. Stress Health. 2004;20:35–41.
Trace SE, Thornton LM, Runfola CD, Lichtenstein P, Pedersen NL, Bulik CM. Sleep problems are associated with binge eating in women. Int J Eat Disord. 2012;45:695–703.
Yeh SS, Brown RF. Disordered eating partly mediates the relationship between poor sleep quality and high body mass index. Eat Behav. 2014;15:291–7.
Tzischinsky O, Latzer Y. Sleep-wake cycles in obese children with and without binge-eating episodes. J Paediatr Child Health. 2006;42:688–93.
Kim KR, Jung YC, Shin MY, Namkoong K, Kim JK, Lee JH. Sleep disturbance in women with eating disorder: prevalence and clinical characteristics. Psychiatry Res. 2010;176:88–90.
Ulman TF, Von Holle A, Torgersen L, Stoltenberg C, Reichborn-Kjennerud T, Bulik CM. Sleep disturbances and binge eating disorder symptoms during and after pregnancy. Sleep. 2012;35:1403–11.
Kessler RC, Berglund PA, Chiu WT, Deitz AC, Hudson JI, Shahly V, et al. The prevalence and correlates of binge eating disorder in the World Health Organization World Mental Health Surveys. Biol Psychiatry. 2013;73:904–14.
Ogilvie RP, Patel SR. The epidemiology of sleep and obesity. Sleep Health. 2017;3:383–8.
Li JTE, Pursey KM, Duncan MJ, Burrows T. Addictive eating and its relation to physical activity and sleep behavior. Nutrients. 2018;10:10
Marino M, Li Y, Rueschman MN, Winkelman JW, Ellenbogen JM, Solet JM. et al. Measuring sleep: accuracy, sensitivity, and specificity of wrist actigraphy compared to polysomnography. Sleep. 2013;36:1747–55.
Manni R, Ratti MT, Tartara A. Nocturnal eating: prevalence and features in 120 insomniac referrals. Sleep. 1997;20:734–8.
Rogers NL, Dinges DF, Allison KC, Maislin G, Martino N, O'Reardon JP. et al. Assessment of sleep in women with night eating syndrome. Sleep. 2006;29:814–9.
Cleator J, Abbott J, Judd P, Sutton C, Wilding JP. Night eating syndrome: implications for severe obesity. Nutr Diabetes. 2012;2:e44
Allison KC, Lundgren JD, O'reardon JP, Geliebter A, Gluck ME, Vinai P, et al. Proposed diagnostic criteria for night eating syndrome. Int J Eat Disord. 2010;43:241–7.
Kucukgoncu S, Midura M, Tek C. Optimal management of night eating syndrome: challenges and solutions. Neuropsychiatr Dis Treat. 2015;11:751–60.
Stunkard AJ, Grace WJ, Wolff HG. The night-eating syndrome; a pattern of food intake among certain obese patients. Am J Med. 1955;19:78–86.
Stunkard AJ. Eating patterns and obesity. Psychiatr Q. 1959;33:284–95.
Lundgren JD, Allison KC, O’Reardon JP, Stunkard AJ. A descriptive study of non-obese persons with night eating syndrome and a weight-matched comparison group. Eat Behav. 2008;9:343–51.
Sassaroli S, Ruggiero GM, Vinai P, Cardetti S, Carpegna G, Ferrato N, et al. Daily and nightly anxiety among patients affected by night eating syndrome and binge eating disorder. Eat Disord. 2009;17:140–5.
Allison KC, Grilo CM, Masheb RM, Stunkard AJ. Binge eating disorder and night eating syndrome: a comparative study of disordered eating. J Consult Clin Psychol. 2005;73:1107–15.
Corwin RL, Babbs RK. Rodent models of binge eating: are they models of addiction? ILAR J. 2012;53:23–34.
Corwin RL, Avena NM, Boggiano MM. Feeding and reward: perspectives from three rat models of binge eating. Physiol Behav. 2011;104:87–97.
Bello NT, Yeh CY, James MH. Reduced sensory-evoked locus coeruleus-norepinephrine neural activity in female rats with a history of dietary-induced binge eating. Front Psychol. 2019;10:1966.
Moore CF, Leonard MZ, Micovic NM, Miczek KA, Sabino V, Cottone P. Reward sensitivity deficits in a rat model of compulsive eating behavior. Neuropsychopharmacology. 2020;45:589–96.
Velázquez-Sánchez C, Ferragud A, Moore CF, Everitt BJ, Sabino V, Cottone P. High trait impulsivity predicts food addiction-like behavior in the rat. Neuropsychopharmacology. 2014;39:2463–72.
Perello M, Valdivia S, García Romero G, Raingo J. Considerations about rodent models of binge eating episodes. Front Psychol. 2014;5:372.
Berner LA, Bocarsly ME, Hoebel BG, Avena NM. Baclofen suppresses binge eating of pure fat but not a sugar-rich or sweet-fat diet. Behav. Pharmacol. 2009;20:631–4.
Davis JF, Melhorn SJ, Shurdak JD, Heiman JU, Tschöp MH, Clegg DJ, et al. Comparison of hydrogenated vegetable shortening and nutritionally complete high-fat diet on limited access-binge behavior in rats. Physiol Behav. 2007;92:924–30.
Howard CE, Porzelius LK. The role of dieting in binge eating disorder: etiology and treatment implications. Clin Psychol Rev. 1999;19:25–44.
Bello NT, Guarda AS, Terrillion CE, Redgrave GW, Coughlin JW, Moran TH. Repeated binge access to a palatable food alters feeding behavior, hormone profile, and hindbrain c-Fos responses to a test meal in adult male rats. Am J Physiol Regul Integr Comp Physiol. 2009;297:R622–631.
Anversa RG, Campbell EJ, Ch’ng SS, Gogos A, Lawrence AJ, Brown RM. A model of emotional stress-induced binge eating in female mice with no history of food restriction. Genes Brain Behav. 2020;19:e12613.
Corwin RL. Binge-type eating induced by limited access in rats does not require energy restriction on the previous day. Appetite. 2004;42:139–42.
Corwin RL, Buda-Levin A. Behavioral models of binge-type eating. Physiol Behav. 2004;82:123–30.
Hagan MM, Wauford PK, Chandler PC, Jarrett LA, Rybak RJ, Blackburn K. A new animal model of binge eating: key synergistic role of past caloric restriction and stress. Physiol Behav. 2002;77:45–54.
Cottone P, Wang X, Park JW, Valenza M, Blasio A, Kwak J, et al. Antagonism of sigma-1 receptors blocks compulsive-like eating. Neuropsychopharmacology. 2012;37:2593–604.
Venner A, Todd WD, Fraigne J, Bowrey H, Eban-Rothschild A, Kaur S. et al. Newly identified sleep-wake and circadian circuits as potential therapeutic targets. Sleep. 2019;42:5
Scammell TE, Arrigoni E, Lipton JO. Neural circuitry of wakefulness and sleep. Neuron. 2017;93:747–65.
Eban-Rothschild A, Appelbaum L, de Lecea L. Neuronal mechanisms for sleep/wake regulation and modulatory drive. Neuropsychopharmacology. 2018;43:937–52.
Bjorness TE, Greene RW. Interaction between cocaine use and sleep behavior: a comprehensive review of cocaine’s disrupting influence on sleep behavior and sleep disruptions influence on reward seeking. Pharmacol Biochem Behav. 2021;206:173194.
Doyle SE, Feng H, Garber G, Menaker M, Lynch WJ. Effects of circadian disruption on methamphetamine consumption in methamphetamine-exposed rats. Psychopharmacology. 2015;232:2169–79.
Mistlberger RE. Circadian food-anticipatory activity: formal models and physiological mechanisms. Neurosci Biobehav Rev. 1994;18:171–95.
Gooley JJ, Schomer A, Saper CB. The dorsomedial hypothalamic nucleus is critical for the expression of food-entrainable circadian rhythms. Nat Neurosci. 2006;9:398–407.
Mistlberger RE. Food-anticipatory circadian rhythms: concepts and methods. Eur J Neurosci. 2009;30:1718–29.
Mistlberger R, Rusak B. Palatable daily meals entrain anticipatory activity rhythms in free-feeding rats: dependence on meal size and nutrient content. Physiol Behav. 1987;41:219–26.
Mendoza J, Angeles-Castellanos M, Escobar C. Entrainment by a palatable meal induces food-anticipatory activity and c-Fos expression in reward-related areas of the brain. Neuroscience. 2005;133:293–303.
Blancas A, González-Garcí a SD, Rodríguez K, Escobar C. Progressive anticipation in behavior and brain activation of rats exposed to scheduled daily palatable food. Neuroscience. 2014;281:44–53.
Hsu CT, Patton DF, Mistlberger RE, Steele AD. Palatable meal anticipation in mice. PLoS ONE. 2010;5:9.
Flôres DE, Bettilyon CN, Yamazaki S. Period-independent novel circadian oscillators revealed by timed exercise and palatable meals. Sci Rep. 2016;6:21945.
Velázquez-Sánchez C, Santos JW, Smith KL, Ferragud A, Sabino V, Cottone P. Seeking behavior, place conditioning, and resistance to conditioned suppression of feeding in rats intermittently exposed to palatable food. Behav Neurosci. 2015;129:219–24.
Johnson WG, Schlundt DG, Barclay DR, Carr-Nangle RE, Engler LB. A naturalistic functional analysis of binge eating. Behav Ther. 1995;26:101–18.
Smyth JM, Wonderlich SA, Sliwinski MJ, Crosby RD, Engel SG, Mitchell JE, et al. Ecological momentary assessment of affect, stress, and binge-purge behaviors: day of week and time of day effects in the natural environment. Int J Eat Disord. 2009;42:429–36.
Stein RI, Kenardy J, Wiseman CV, Dounchis JZ, Arnow BA, Wilfley DE. What’s driving the binge in binge eating disorder?: A prospective examination of precursors and consequences. Int J Eat Disord. 2007;40:195–203.
Escobar C, Salgado R, Rodriguez K, Blancas Vázquez AS, Angeles-Castellanos M, Buijs RM. Scheduled meals and scheduled palatable snacks synchronize circadian rhythms: consequences for ingestive behavior. Physiol Behav. 2011;104:555–61.
Webb IC, Baltazar RM, Lehman MN, Coolen LM. Bidirectional interactions between the circadian and reward systems: is restricted food access a unique zeitgeber? Eur J Neurosci. 2009;30:1739–48.
Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry. 2005;162:1403–13.
Baldo BA, Kelley AE. Discrete neurochemical coding of distinguishable motivational processes: insights from nucleus accumbens control of feeding. Psychopharmacology. 2007;191:439–59.
Liu Z, Wang Y, Cai L, Li Y, Chen B, Dong Y, et al. Prefrontal cortex to accumbens projections in sleep regulation of reward. J Neurosci. 2016;36:7897–910.
Chen B, Wang Y, Liu X, Liu Z, Dong Y, Huang YH. Sleep regulates incubation of cocaine craving. J Neurosci. 2015;35:13300–10.
Roane BM, Taylor DJ. Adolescent insomnia as a risk factor for early adult depression and substance abuse. Sleep. 2008;31:1351–6.
Wong MM, Brower KJ, Nigg JT, Zucker RA. Childhood sleep problems, response inhibition, and alcohol and drug outcomes in adolescence and young adulthood. Alcohol, Clin Exp Res. 2010;34:1033–44.
Brower KJ, Perron BE. Sleep disturbance as a universal risk factor for relapse in addictions to psychoactive substances. Med Hypotheses. 2010;74:928–33.
Morgan PT, Pace-Schott EF, Sahul ZH, Coric V, Stickgold R, Malison RT Sleep, sleep-dependent procedural learning and vigilance in chronic cocaine users: evidence for occult insomnia. Drug alcohol Depend. 2006;82:238–49.
Pace-Schott EF, Stickgold R, Muzur A, Wigren PE, Ward AS, Hart CL. et al. Sleep quality deteriorates over a binge-abstinence cycle in chronic smoked cocaine users. Psychopharmacology. 2005;179:873–83.
Pace-Schott EF, Stickgold R, Muzur A, Wigren PE, Ward AS, Hart CL, et al. Cognitive performance by humans during a smoked cocaine binge-abstinence cycle. Am J Drug Alcohol Abuse. 2005;31:571–91.
Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H. et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92:92–585.
de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA. 1998;95:95–7.
Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469–474. https://doi.org/10.1016/S0896-6273(00)00058-1.
Kilduff TS, Peyron C. The hypocretin/orexin ligand-receptor system: implications for sleep and sleep disorders. Trends Neurosci. 2000;23:359–65. https://doi.org/10.1016/s0166-2236(00)01594-0.
Borgland SL, Taha SA, Sarti F, Fields HL, Bonci A. Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. Neuron. 2006;49:589–601.
Thompson JL, Borgland SL. A role for hypocretin/orexin in motivation. Behav Brain Res. 2011;217:446–53.
James MH, Charnley JL, Levi EM, Jones E, Yeoh JW, Smith DW, et al. Orexin-1 receptor signalling within the ventral tegmental area, but not the paraventricular thalamus, is critical to regulating cue-induced reinstatement of cocaine-seeking. Int J Neuropsychopharmacol. 2011;14:684–90.
Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X. et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999;98:365–76.
Kisanuki Y. The role of orexin receptor type-1 (OX1R) in the regulation of sleep. Sleep. 2000;23:A91
Hondo M, Nagai K, Ohno K, Kisanuki Y, Willie JT, Watanabe T, et al. Histamine-1 receptor is not required as a downstream effector of orexin-2 receptor in maintenance of basal sleep/wake states. Acta Physiol. 2010;198:287–94.
Barson JR. Orexin/hypocretin and dysregulated eating: promotion of foraging behavior. Brain Res. 2020;1731:145915.
Mahler SV, Moorman DE, Smith RJ, James MH, Aston-Jones G. Motivational activation: a unifying hypothesis of orexin/hypocretin function. Nat Neurosci. 2014;17:1298–303.
Campbell EJ, Barker DJ, Nasser HM, Kaganovsky K, Dayas CV, Marchant NJ. Cue-induced food seeking after punishment is associated with increased Fos expression in the lateral hypothalamus and basolateral and medial amygdala. Behav Neurosci. 2017;131:155–67.
Dayas CV, McGranahan TM, Martin-Fardon R, Weiss F. Stimuli linked to ethanol availability activate hypothalamic CART and orexin neurons in a reinstatement model of relapse. Biol Psychiatry. 2008;63:152–7.
James MH, Stopper CM, Zimmer BA, Koll NE, Bowrey HE, Aston-Jones G. Increased number and activity of a lateral subpopulation of hypothalamic orexin/hypocretin neurons underlies the expression of an addicted state in rats. Biol Psychiatry. 2019;85:925–35.
Martin-Fardon R, Cauvi G, Kerr TM, Weiss F. Differential role of hypothalamic orexin/hypocretin neurons in reward seeking motivated by cocaine versus palatable food. Addiction Biol. 2018;23:6–15.
Choi DL, Davis JF, Fitzgerald ME, Benoit SC. The role of orexin-A in food motivation, reward-based feeding behavior and food-induced neuronal activation in rats. Neuroscience. 2010;167:11–20.
Castro DC, Terry RA, Berridge KC. Orexin in rostral hotspot of nucleus accumbens enhances sucrose /‘Liking/' and intake but scopolamine in caudal shell shifts /‘Liking/' toward /‘Disgust/' and /‘Fear/'. Neuropsychopharmacology 2016;41:2101–11.
Terrill SJ, Hyde KM, Kay KE, Greene HE, Maske CB, Knierim AE, et al. Ventral tegmental area orexin 1 receptors promote palatable food intake and oppose postingestive negative feedback. Am J Physiol Regulatory, Integr Comp Physiol. 2016;311:R592–599.
Barson JR, Ho HT, Leibowitz SF. Anterior thalamic paraventricular nucleus is involved in intermittent access ethanol drinking: role of orexin receptor 2. Addict Biol. 2015;20:469–81.
Espana RA, Melchior JR, Roberts DC, Jones SR. Hypocretin 1/orexin A in the ventral tegmental area enhances dopamine responses to cocaine and promotes cocaine self-administration. Psychopharmacology. 2011;214:415–26.
Matzeu A, Kerr TM, Weiss F, Martin-Fardon R. Orexin-A/Hypocretin-1 mediates cocaine-seeking behavior in the posterior paraventricular nucleus of the thalamus via Orexin/Hypocretin Receptor-2. J Pharmacol Exp Ther. 2016;359:273–9.
Wang B, You ZB, Wise RA. Reinstatement of cocaine seeking by hypocretin (orexin) in the ventral tegmental area: independence from the local corticotropin-releasing factor network. Biol Psychiatry. 2009;65:857–62.
Boutrel B, Kenny PJ, Specio SE, Martin-Fardon R, Markou A, Koob GF, et al. Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proc Natl Acad Sci USA. 2005;102:19168–73.
Piccoli L, Micioni Di Bonaventura MV, Cifani C, Costantini VJ, Massagrande M, Montanari D, et al. Role of orexin-1 receptor mechanisms on compulsive food consumption in a model of binge eating in female rats. Neuropsychopharmacology. 2012;37:1999–2011.
Vickers SP, Hackett D, Murray F, Hutson PH, Heal DJ. Effects of lisdexamfetamine in a rat model of binge-eating. J Psychopharmacol. 2015;29:1290–307.
Alcaraz-Iborra M, Carvajal F, Lerma-Cabrera JM, Valor LM, Cubero I. Binge-like consumption of caloric and non-caloric palatable substances in ad libitum-fed C57BL/6J mice: pharmacological and molecular evidence of orexin involvement. Behav. Brain Res. 2014;272:93–9.
Rorabaugh JM, Stratford JM, Zahniser NR. A relationship between reduced nucleus accumbens shell and enhanced lateral hypothalamic orexin neuronal activation in long-term fructose bingeing behavior. PLoS ONE. 2014;9:e95019.
Cason AM, Aston-Jones G. Attenuation of saccharin-seeking in rats by orexin/hypocretin receptor 1 antagonist. Psychopharmacology. 2013;228:499–507.
Cason AM, Aston-Jones G. Role of orexin/hypocretin in conditioned sucrose-seeking in female rats. Neuropharmacology. 2014;86:97–102.
Jupp B, Krivdic B, Krstew E, Lawrence AJ. The orexin(1) receptor antagonist SB-334867 dissociates the motivational properties of alcohol and sucrose in rats. Brain Res. 2011;1391:54–59.
Nair SG, Golden SA, Shaham Y. Differential effects of the hypocretin 1 receptor antagonist SB 334867 on high-fat food self-administration and reinstatement of food seeking in rats. Br J Pharmacol. 2008;154:406–16.
Brown RM, Khoo SY-S, Lawrence AJ. Central orexin (hypocretin) 2 receptor antagonism reduces ethanol self-administration, but not cue-conditioned ethanol-seeking, in ethanol-preferring rats. Int J Neuropsychopharmacol. 2013;16:2067–79.
Shoblock JR, Welty N, Aluisio L, Fraser I, Motley ST, Morton K. et al. Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement. Psychopharmacology. 2011;215:191–203.
Borgland SL, Chang SJ, Bowers MS, Thompson JL, Vittoz N, Floresco SB, et al. Orexin A/hypocretin-1 selectively promotes motivation for positive reinforcers. J Neurosci. 2009;29:11215–25.
Espana RA, Oleson EB, Locke JL, Brookshire BR, Roberts DC, Jones SR. The hypocretin-orexin system regulates cocaine self-administration via actions on the mesolimbic dopamine system. Eur J Neurosci. 2010;31:336–48.
Wiskerke J, James MH, Aston-Jones G. The orexin-1 receptor antagonist SB-334867 reduces motivation, but not inhibitory control, in a rat stop signal task. Brain Res. 2020;1731:146222. https://doi.org/10.1016/j.brainres.2019.04.017.
Matzeu A, Martin-Fardon R. Blockade of Orexin receptors in the posterior paraventricular nucleus of the thalamus prevents stress-induced reinstatement of reward-seeking behavior in rats with a history of ethanol dependence. Front Integr Neurosci. 2020;14:599710.
James MH, Yeoh JW, Graham BA, Dayas CV. Insights for developing pharmacological treatments for psychostimulant relapse targeting hypothalamic peptide systems. J Addict Res Ther. 2012;S4:008.
Martin-Fardon R, Weiss F. Blockade of hypocretin receptor-1 preferentially prevents cocaine seeking: comparison with natural reward seeking. Neuroreport. 2014;25:485–8.
Freeman LR, Bentzley BS, James MH, Aston-Jones G. Sex differences in demand for highly palatable foods: role of the Orexin system. Int. J. Neuropsychopharmacol. 2020.
White CL, Ishii Y, Mendoza T, Upton N, Stasi LP, Bray GA. et al. Effect of a selective OX1R antagonist on food intake and body weight in two strains of rats that differ in susceptibility to dietary-induced obesity. Peptides. 2005;26:2331–8.
James MH, Bowrey HE, Stopper CM, Aston-Jones G. Demand elasticity predicts addiction endophenotypes and the therapeutic efficacy of an orexin/hypocretin-1 receptor antagonist in rats. Eur J Neurosci. 2019;50:2602–12.
Fragale JE, Pantazis CB, James MH, Aston-Jones G. The role of orexin-1 receptor signaling in demand for the opioid fentanyl. Neuropsychopharmacology. 2019;44:1690–7.
Fragale JE, James MH, Aston-Jones G. Intermittent self-administration of fentanyl induces a multifaceted addiction state associated with persistent changes in the orexin system. Addiction Biol. 2020;26:e12946.
Mohammadkhani A, Fragale JE, Pantazis CB, Bowrey HE, James MH, Aston-Jones G. Orexin-1 receptor signaling in ventral pallidum regulates motivation for the opioid remifentanil. J Neurosci. 2019;39:9831–40. https://doi.org/10.1523/JNEUROSCI.0255-19.2019.
Mohammadkhani A, James MH, Pantazis CB, Aston-Jones G. Persistent effects of the orexin-1 receptor antagonist SB-334867 on motivation for the fast acting opioid remifentanil. Brain Res. 2019;1731:146461.
LeSage MG, Perry JL, Kotz CM, Shelley D, Corrigall WA. Nicotine self-administration in the rat: effects of hypocretin antagonists and changes in hypocretin mRNA. Psychopharmacology. 2010;209:203–12.
James MH, Fragale JE, O’Connor SL, Zimmer BA, Aston-Jones G. The orexin (hypocretin) neuropeptide system is a target for novel therapeutics to treat cocaine use disorder with alcohol coabuse. Neuropharmacology. 2020;183:108359
Prince CD, Rau AR, Yorgason JT, España RA. Hypocretin/Orexin regulation of dopamine signaling and cocaine self-administration is mediated predominantly by Hypocretin Receptor 1. ACS Chem Neurosci. 2015;6:138–46.
Lawrence AJ, Cowen MS, Yang HJ, Chen F, Oldfield B. The orexin system regulates alcohol-seeking in rats. Br J Pharmacol. 2006;148:752–9.
Hollander JA, Pham D, Fowler CD, Kenny PJ. Hypocretin-1 receptors regulate the reinforcing and reward-enhancing effects of cocaine: pharmacological and behavioral genetics evidence. Front Behav Neurosci. 2012;6:47.
Smith RJ, Tahsili-Fahadan P, Aston-Jones G. Orexin/hypocretin is necessary for context-driven cocaine-seeking. Neuropharmacology. 2010;58:179–84.
Smith RJ, Aston-Jones G. Orexin/hypocretin 1 receptor antagonist reduces heroin self-administration and cue-induced heroin seeking. Eur J Neurosci. 2012;35:798–804.
Matzeu A, Martin-Fardon R. Targeting the Orexin system for prescription opioid use disorder. Brain Sci. 2020;10:4.
Martin-Fardon, R, Weiss, F. N-2-methyl-6-benzoxazolyl)-N’-1,5-naphthyridin-4-yl urea (SB334867), a hypocretin receptor-1 antagonist, preferentially prevents ethanol seeking: comparison with natural reward seeking. Addict Biol. 2014;19:233–6.
Hopf FW. Recent perspectives on orexin/hypocretin promotion of addiction-related behaviors. Neuropharmacology. 2020;168:108013
Kwok C, Lei K, Pedrozo V, Anderson L, Ghotra S, Walsh M, et al. Differential importance of nucleus accumbens Ox1Rs and AMPARs for female and male mouse binge alcohol drinking. Sci Rep. 2021;11:231.
Gentile TA, Simmons SJ, Watson MN, et al. Effects of Suvorexant, a dual orexin/hypocretin receptor antagonist, on impulsive behavior associated with cocaine. Neuropsychopharmacology. 2018;43:1001–9. https://doi.org/10.1038/npp.2017.158.
Muschamp JW, Hollander JA, Thompson JL, Voren G, Hassinger LC, Onvani S, et al. Hypocretin (orexin) facilitates reward by attenuating the antireward effects of its cotransmitter dynorphin in ventral tegmental area. Proc Natl Acad Sci USA. 2014;111:E1648–1655.
Calva CB, Fadel JR. Intranasal administration of orexin peptides: mechanisms and therapeutic potential for age-related cognitive dysfunction. Brain Res. 2020;1731:145921. https://doi.org/10.1016/j.brainres.2018.08.024.
Adam JA, Menheere PP, van Dielen FM, Soeters PB, Buurman WA, Greve JW. Decreased plasma orexin-A levels in obese individuals. Int J Obes Relat Metab Disord. 2002;26:274–6.
Gupta A, Miegueu P, Lapointe M, Poirier P, Martin J, Bastien M, et al. Acute post-bariatric surgery increase in orexin levels associates with preferential lipid profile improvement. PLoS ONE. 2014;9:e84803.
Nishino S. Clinical and neurobiological aspects of narcolepsy. Sleep Med. 2007;8:373–99.
Funato H, Tsai AL, Willie JT, Kisanuki Y, Williams SC, Sakurai T, et al. Enhanced orexin receptor-2 signaling prevents diet-induced obesity and improves leptin sensitivity. Cell Metab. 2009;9:64–76.
Kotz C, Nixon J, Butterick T, Perez-Leighton C, Teske J, Billington C. Brain orexin promotes obesity resistance. Ann N Y Acad Sci. 2012;1264:72–86.
Teske JA, Levine AS, Kuskowski M, Levine JA, Kotz CM. Elevated hypothalamic orexin signaling, sensitivity to orexin A, and spontaneous physical activity in obesity-resistant rats. Am J Physiol Regul Integr Comp Physiol. 2006;291:R889–899.
Kotz C, Nixon J, Butterick T, Perez-Leighton C, Teske J, Billington C. Brain orexin promotes obesity resistance. Ann N Y Acad Sci. 2012;1264:72–86.
Lemus MB, Bayliss JA, Lockie SH, Santos VV, Reichenbach A, Stark R. et al. A stereological analysis of NPY, POMC, Orexin, GFAP astrocyte, and Iba1 microglia cell number and volume in diet-induced obese male mice. Endocrinology. 2015;156:1701–13.
Wortley KE, Chang GQ, Davydova Z, Leibowitz SF. Peptides that regulate food intake: orexin gene expression is increased during states of hypertriglyceridemia. Am J Physiol Regul Integr Comp Physiol. 2003;284:R1454–65.
Morganstern I, Chang GQ, Karatayev O, Leibowitz SF. Increased orexin and melanin-concentrating hormone expression in the perifornical lateral hypothalamus of rats prone to overconsuming a fat-rich diet. Pharmacol, Biochem Behav. 2010;96:413–22.
Xi MC, Morales FR, Chase MH. Effects on sleep and wakefulness of the injection of hypocretin-1 (orexin-A) into the laterodorsal tegmental nucleus of the cat. Brain Res. 2001;901:259–64.
Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C. et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell . 1999;98:437–51.
Fujiki N, Yoshida Y, Ripley B, Mignot E, Nishino S. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep. 2003;26:953–9.
Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, Sinton CM. et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron. 2001;30:345–54.
Yoshida Y, Fujiki N, Nakajima T, Ripley B, Matsumura H, Yoneda H, et al. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur J Neurosci. 2001;14:1075–81.
Estabrooke IV, McCarthy MT, Ko E, Chou TC, Chemelli RM, Yanagisawa M, et al. Fos expression in orexin neurons varies with behavioral state. J Neurosci. 2001;21:1656–62.
Adamantidis AR, Zhang F, Aravanis AM, Deisseroth K, de Lecea L. Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature. 2007;450:420–4.
Carter ME, Adamantidis A, Ohtsu H, Deisseroth K, de Lecea L. Sleep homeostasis modulates hypocretin-mediated sleep-to-wake transitions. J Neurosci. 2009;29:29–49.
Sasaki K, Suzuki M, Mieda M, Tsujino N, Roth B, Sakurai T. Pharmacogenetic modulation of orexin neurons alters sleep/wakefulness states in mice. PLoS ONE. 2011;6:e20360.
Tsunematsu T, Kilduff TS, Boyden ES, Takahashi S, Tominaga M, Yamanaka A. Acute optogenetic silencing of orexin/hypocretin neurons induces slow-wave sleep in mice. J Neurosci. 2011;31:10529–39.
Gerhardstein R, Day R, Rosenthal L. Narcolepsy and other causes of excessive daytime sleepiness. Respir Care Clin N Am. 1999;5:427–46, viii-ix.
Slowik JM, Collen JF, Yow AG. Narcolepsy. StatPearls. 2020.
Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000;355:39–40.
Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M. et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000;27:27–74.
Rhyne DN, Anderson SL. Suvorexant in insomnia: efficacy, safety and place in therapy. Ther Adv Drug Saf. 2015;6:189–95.
Norman JL, Anderson SL. Novel class of medications, orexin receptor antagonists, in the treatment of insomnia—critical appraisal of suvorexant. Nat Sci Sleep. 2016;8:239–47.
Janto K, Prichard JR, Pusalavidyasagar S. An update on dual orexin receptor antagonists and their potential role in insomnia therapeutics. J Clin Sleep Med. 2018;14:1399–408.
Muehlan C, Vaillant C, Zenklusen I, Kraehenbuehl S, Dingemanse J. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert Opin Drug Metab Toxicol. 2020;16:1063–78.
Recourt K, de Boer P, Zuiker R, Luthringer R, Kent J, van der Ark P, et al. The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder. Transl Psychiatry. 2019;9:216.
Dugovic C, Shelton JE, Aluisio LE, Fraser IC, Jiang X, Sutton SW, et al. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J Pharmacol Exp therapeutics. 2009;330:142–51.
Cox CD, Breslin MJ, Whitman DB, Schreier JD, McGaughey GB, Bogusky MJ, et al. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H -1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem. 2010;53:5320–32.
Winrow CJ, Gotter AL, Cox CD, Doran SM, Tannenbaum PL, Breslin MJ, et al. Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. J Neurogenet. 2011;25:52–61.
Herring WJ, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K. et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012;79:2265–74.
Ardeljan AD, Hurezeanu R. Lemborexant. StatPearls; 2020.
Bonaventure P, Shelton J, Yun S, Nepomuceno D, Sutton S, Aluisio L, et al. Characterization of JNJ-42847922, a selective Orexin-2 receptor antagonist, as a clinical candidate for the treatment of insomnia. J Pharmacol Exp Ther. 2015;354:471–82.
Guirguis WR. Sleepwalking as a symptom of bulimia. Br Med J (Clin Res Ed). 1986;293:587–8.
Iwasa T, Matsuzaki T, Mayila Y, Yano K, Irahara M. Developmental changes in hypothalamic SF-1, POMC, and ERα mRNA expression and their sensitivity to fasting in male and female rats. Endocr J. 2017;64:1157–63.
Tanno S, Terao A, Okamatsu-Ogura Y, Kimura K. Hypothalamic prepro-orexin mRNA level is inversely correlated to the non-rapid eye movement sleep level in high-fat diet-induced obese mice. Obes Res Clin Pract. 2013;7:e251–7.
True C, Arik A, Lindsley S, Kirigiti M, Sullivan E, Kievit P. Early high-fat diet exposure causes dysregulation of the Orexin and Dopamine neuronal populations in nonhuman primates. Front Endocrinol (Lausanne). 2018;9:508.
Beck B, Kozak R, Moar KM, Mercer JG. Hypothalamic orexigenic peptides are overexpressed in young Long-Evans rats after early life exposure to fat-rich diets. Biochem Biophys Res Commun. 2006;342:452–8.
Chen P-Y, Chen C-H, Chang C-K, Kao CF, Lu ML, Lin SK, et al. Orexin-A levels in relation to the risk of metabolic syndrome in patients with schizophrenia taking antipsychotics. Int J Neuropsychopharmacol. 2018;22:28–36.
Thannickal TC, John J, Shan L, Swaab DF, Wu MF, Ramanathan L, et al. Opiates increase the number of hypocretin-producing cells in human and mouse brain and reverse cataplexy in a mouse model of narcolepsy. Sci Transl Med. 2018;10:447.
Collier AD, Halkina V, Min SS, Roberts MY, Campbell SD, Camidge K, et al. Embryonic ethanol exposure affects the early development, migration, and location of hypocretin/orexin neurons in zebrafish. Alcohol Clin Exp Res. 2019;43:1702–13.
Collier AD, Min SS, Campbell SD, Roberts MY, Camidge K, Leibowitz SF. Maternal ethanol consumption before paternal fertilization: stimulation of hypocretin neurogenesis and ethanol intake in zebrafish offspring. Prog Neuropsychopharmacol Biol Psychiatry. 2020;96:109728.
Yeoh JW, James MH, Adams CD, Bains JS, Sakurai T, Aston-Jones G. et al. Activation of lateral hypothalamic group III metabotropic glutamate receptors suppresses cocaine-seeking following abstinence and normalizes drug-associated increases in excitatory drive to orexin/hypocretin cells. Neuropharmacology. 2019;154:22–33.
Yeoh JW, James MH, Graham BA, Dayas CV. Electrophysiological characteristics of paraventricular thalamic (PVT) neurons in response to cocaine and cocaine- and amphetamine-regulated transcript (CART). Front Behav Neurosci. 2014;8:280.
Horvath TL, Gao XB. Input organization and plasticity of hypocretin neurons: possible clues to obesity’s association with insomnia. Cell Metab. 2005;1:279–86.
Laperchia C, Imperatore R, Azeez IA, Del Gallo F, Bertini G, Grassi-Zucconi G, et al. The excitatory/inhibitory input to orexin/hypocretin neuron soma undergoes day/night reorganization. Brain Struct Funct. 2017;222:3847–59.
Bunney PE, Zink AN, Holm AA, Billington CJ, Kotz CM. Orexin activation counteracts decreases in nonexercise activity thermogenesis (NEAT) caused by high-fat diet. Physiol Behav. 2017;176:139–48.
Moorman DE, Aston-Jones G. Orexin/hypocretin modulates response of ventral tegmental dopamine neurons to prefrontal activation: diurnal influences. J Neurosci. 2010;30:15585–99.
Horvath TL, Diano S, van den Pol AN. Synaptic interaction between hypocretin (orexin) and neuropeptide Y cells in the rodent and primate hypothalamus: a novel circuit implicated in metabolic and endocrine regulations. J Neurosci. 1999;19:19–1087.
Pollak Dorocic I, Fürth D, Xuan Y, Johansson Y, Pozzi L, Silberberg G. et al. A whole-brain atlas of inputs to serotonergic neurons of the dorsal and median raphe nuclei. Neuron. 2014;83:663–78.
Muraki Y, Yamanaka A, Tsujino N, Kilduff TS, Goto K, Sakurai T. Serotonergic regulation of the orexin/hypocretin neurons through the 5-HT1A receptor. J Neurosci. 2004;24:7159–66.
Saito YC, Tsujino N, Abe M, Yamazaki M, Sakimura K, Sakurai T. Serotonergic input to Orexin neurons plays a role in maintaining wakefulness and REM sleep architecture. Front Neurosci. 2018;12:892.
Allsopp MR, Zaiwalla Z. Narcolepsy. Arch Dis Child. 1992;67:302–6.
Fortuyn HA, Swinkels S, Buitelaar J, Renier WO, Furer JW, Rijnders CA. et al. High prevalence of eating disorders in narcolepsy with cataplexy: a case-control study. Sleep. 2008;31:335–41.
van Holst RJ, van der Cruijsen L, van Mierlo P, Lammers GJ, Cools R, Overeem S. et al. Aberrant food choices after satiation in human Orexin-deficient narcolepsy type 1. Sleep. 2016;39:1951–9.
Dimitrova A, Fronczek R, Van der Ploeg J, Scammell T, Gautam S, Pascual-Leone A, et al. Reward-seeking behavior in human narcolepsy. J Clin Sleep Med. 2011;7:293–300.
Dauvilliers Y, Montplaisir J, Molinari N, Carlander B, Ondze B, Besset A. et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology. 2001;57:2029–33.
González JA, Jensen LT, Iordanidou P, Strom M, Fugger L, Burdakov D. Inhibitory interplay between Orexin neurons and eating. Curr Biol. 2016;26:2486–91.
Dahmen N, Becht J, Engel A, Thommes M, Tonn P. Prevalence of eating disorders and eating attacks in narcolepsy. Neuropsychiatr Dis Treat. 2008;4:257–61.
Sharma S, Kavuru M. Sleep and metabolism: an overview. Int J Endocrinol. 2010;2010:270832
O’Connor SL, Fragale JE, James MH, Aston-Jones G. The dual orexin/hypocretin receptor antagonist suvorexant reduces addiction-like behaviors for the opioid fentanyl [Preprint]. 2020. Available from: https://www.biorxiv.org/content/10.1101/2020.04.25.061887v1.
Gamble MC, Katsuki F, McCoy JG, Strecker RE, McKenna JT. The dual orexinergic receptor antagonist DORA-22 improves the sleep disruption and memory impairment produced by a rodent insomnia model. Sleep. 2019;43:3
James MH, Fragale JE, Aurora RN, Cooperman NA, Langleben DD, Aston-Jones G. Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer? Neuropsychopharmacology. 2020;45:717–19.
Kotorii N. Treatment strategies when multiple sleep disturbances coexist. The abstract of Japanese society of sleep research meeting 192; Japan, 2015.
Ono H, Kanbayashi T, Iwaki S, et al. Clinical experience with a dual orexin receptor antagonist, Suvorexant (Belsomra) in Japan. J Sleep Disord Med Care. 2018;1:1–5.
Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001;2:297–307. https://doi.org/10.1016/s1389-9457(00)00065-4.
Figure was prepared using BioRender.
Conflict of interest
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Mehr, J.B., Mitchison, D., Bowrey, H.E. et al. Sleep dysregulation in binge eating disorder and “food addiction”: the orexin (hypocretin) system as a potential neurobiological link. Neuropsychopharmacol. (2021). https://doi.org/10.1038/s41386-021-01052-z